Announcements
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
- XOMA Announces Stock Repurchase Program of up to $50 Million
More ▼
Key statistics
As of last trade XOMA Corp (X0M1:DUS) traded at 22.40, -6.67% below its 52-week high of 24.00, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.40 |
---|---|
High | 22.40 |
Low | 22.40 |
Bid | 22.60 |
Offer | 25.00 |
Previous close | 22.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 11.64m |
Free float | 11.59m |
P/E (TTM) | -- |
Market cap | 286.11m USD |
EPS (TTM) | -4.04 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 07:10 BST.
More ▼